Biopharmaceutical aspects of ritodrine retard in pregnant women.
Biopharmaceutical aspects of the new sustained-release formulation of ritodrine, a tocolytic agent, were studied in 9 patients with preterm labour. A mean bioavailability of 26% (range 22%-32%) was estimated after the 4th day of treatment (steady state). A.U.C.'s from oral administration were found to correlate well with those measured in i.v. therapy in the same patients (r = 0.92; p = 0.0004). It was concluded that differences in bioavailability of ritodrine-retard are small enough to enable clinicians, using this sustained release preparation, to make fair estimations of the oral dosage, needed to replace the initial i.v. treatment.
Essed
G G
GG
Department of Obstetrics and Gynaecology, Academic Hospital, State University of Limburg, Maastricht, The Netherlands.
Struyker Boudier
H A
HA
Van Zijl
J A
JA
D000284:Administration, Oral; D000328:Adult; D001702:Biopharmaceutics; D003692:Delayed-Action Preparations; D005260:Female; D005865:Gestational Age; D006801:Humans; D007275:Injections, Intravenous; D007752:Obstetric Labor, Premature / Q000517:prevention & control*; D011247:Pregnancy; D012312:Ritodrine / Q000008:administration & dosage / Q000493:pharmacokinetics* / Q000627:therapeutic use
D003692:Delayed-Action Preparations; D012312:Ritodrine